THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

BIVICTRIX THERAPEUTICS PLC

("BiVictriX" or the "Company")

 

 

Appointment of Adrian Howd as Chief Financial Officer

and Chief Business Officer

 

Alderley Park, 03 October 2023 - BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a differentiated approach to develop novel, next-generation anti-cancer precision Antibody Drug Conjugates, offering substantially improved cancer cell selectivity and therapeutic activity, today announces that it has appointed Adrian Howd, PhD as combined Chief Financial Officer ("CFO") and Chief Business Officer ("CBO"). Alex Hughes will be stepping down from his position as CFO on 13 October.

 

Adrian joins BiVictriX with over 20 years of strategic financial and commercial experience in the biopharmaceutical industry, having held various financial roles, private and public executive management positions and board roles across the sector. During his career to date he has led multiple asset and corporate business development transactions, as well as numerous equity capital market fundraises totalling over €430 million. Adrian possesses substantial equity capital markets experience in the UK and overseas, gained during his previous senior roles at Berenberg Bank, ABN Amro and Nomura.   

 

Adrian has also held various senior management roles, including Chief Investment Officer and Chief Executive Officer at investment firm, Malin plc, where he led the Company to its debut on the Irish Stock Exchange in one of the largest European life science initial public offerings to date.

 

At Malin, Adrian led investments in and served on the boards of both Immunocore and Kymab, two "platform to therapeutic" UK-based companies, both of which achieved multibillion USD exits via a NASDAQ IPO and a trade sale to Sanofi respectively.

 

Tiffany Thorn, Chief Executive Officer of BiVictriX Therapeutics plc, added: "We are delighted to welcome Adrian as Chief Financial Officer and Chief Business Officer. His substantial financial acumen, combined with his strong track record of strategic and operational success with UK oncology businesses will be invaluable, as we look to secure partnership deals and accelerate BiVictriX towards our next phase of development. On behalf of the entire team, I would like to express my thanks to Alex for his contributions to the Company and wish him all the best in his future endeavours."

 

Adrian Howd, newly appointed Chief Financial Officer and Chief Business Officer of BiVictriX Therapeutics plc, said: "BiVictriX Therapeutics has reached a critical inflection point, having achieved compelling and differentiated pre-clinical data for its lead asset as well as broadening the technology pipeline and building the foundations of a robust, patent-protected portfolio. I strongly believe in the potential of the Bi-Cygni® Platform to revolutionise cancer therapy and the Company has multiple strategic options, for its lead asset and also in the wider solid tumour space. At this point in the Company's evolution, I see parallels between other companies I have successfully worked with in the oncology space and I am looking forward to joining Tiffany and the wider BiVictriX team to maximise shareholder value from the science."

 

 

About BiVictriX Therapeutics plc

BiVictriX is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities.

 

The Company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni® fingerprints", on tumour cells, which are largely absent from healthy cells.

 

BiVictriX has established a growing proprietary library of cancer-specific Bi-Cygni® fingerprints, which enable the Company to target a diverse array of different cancer types. The Company utilises these novel Bi-Cygni® fingerprints, together with the Company's novel Antibody Drug Conjugate therapeutic design, to develop more effective and safer therapeutics to target cancers that are expected to constitute orphan indications and areas of high unmet medical need.

 

Find out more about BiVictriX online at www.bivictrix.com